PL4230209T3 - Kompozycja farmaceutyczna, złożona formulacja farmaceutyczna i zestaw złożonej formulacji do zapobiegania przewlekłemu zapaleniu wątroby typu b lub leczenia takiego zapalenia, z których każde zawiera jako składnik czynny doustny środek przeciwwirusowy i szczepionkę terapeutyczną zawierającą lipopeptyd i adiuwant poli(i:c) - Google Patents
Kompozycja farmaceutyczna, złożona formulacja farmaceutyczna i zestaw złożonej formulacji do zapobiegania przewlekłemu zapaleniu wątroby typu b lub leczenia takiego zapalenia, z których każde zawiera jako składnik czynny doustny środek przeciwwirusowy i szczepionkę terapeutyczną zawierającą lipopeptyd i adiuwant poli(i:c)Info
- Publication number
- PL4230209T3 PL4230209T3 PL21894866.9T PL21894866T PL4230209T3 PL 4230209 T3 PL4230209 T3 PL 4230209T3 PL 21894866 T PL21894866 T PL 21894866T PL 4230209 T3 PL4230209 T3 PL 4230209T3
- Authority
- PL
- Poland
- Prior art keywords
- combined formulation
- pharmaceutical
- lipopeptide
- adjuvant
- poly
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 2
- 239000000203 mixture Substances 0.000 title 2
- 208000000419 Chronic Hepatitis B Diseases 0.000 title 1
- 108010028921 Lipopeptides Proteins 0.000 title 1
- 239000004480 active ingredient Substances 0.000 title 1
- 239000002671 adjuvant Substances 0.000 title 1
- 239000003443 antiviral agent Substances 0.000 title 1
- 208000002672 hepatitis B Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 229940021747 therapeutic vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200154793A KR102292147B1 (ko) | 2020-11-18 | 2020-11-18 | 경구용 항바이러스제 및 리포펩타이드와 폴리(i:c) 아쥬반트를 포함한 치료백신을 유효성분으로 포함하는 만성 b형 간염의 예방 또는 치료용 약제학적 조성물, 약제학적 병용제제, 병용제 키트 |
| PCT/KR2021/013317 WO2022108094A1 (ko) | 2020-11-18 | 2021-09-29 | 경구용 항바이러스제 및 리포펩타이드와 폴리(i:c) 아쥬반트를 포함한 치료백신을 유효성분으로 포함하는 만성 b형 간염의 예방 또는 치료용 약제학적 조성물, 약제학적 병용제제, 병용제 키트 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4230209T3 true PL4230209T3 (pl) | 2025-02-24 |
Family
ID=77499229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21894866.9T PL4230209T3 (pl) | 2020-11-18 | 2021-09-29 | Kompozycja farmaceutyczna, złożona formulacja farmaceutyczna i zestaw złożonej formulacji do zapobiegania przewlekłemu zapaleniu wątroby typu b lub leczenia takiego zapalenia, z których każde zawiera jako składnik czynny doustny środek przeciwwirusowy i szczepionkę terapeutyczną zawierającą lipopeptyd i adiuwant poli(i:c) |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230405112A1 (pl) |
| EP (1) | EP4230209B1 (pl) |
| KR (1) | KR102292147B1 (pl) |
| CN (1) | CN116568309B (pl) |
| AU (1) | AU2021382954B2 (pl) |
| ES (1) | ES2991384T3 (pl) |
| MX (1) | MX2023005431A (pl) |
| PL (1) | PL4230209T3 (pl) |
| WO (1) | WO2022108094A1 (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102292147B1 (ko) * | 2020-11-18 | 2021-08-23 | 주식회사 차백신연구소 | 경구용 항바이러스제 및 리포펩타이드와 폴리(i:c) 아쥬반트를 포함한 치료백신을 유효성분으로 포함하는 만성 b형 간염의 예방 또는 치료용 약제학적 조성물, 약제학적 병용제제, 병용제 키트 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20020020748A (ko) * | 1999-06-22 | 2002-03-15 | 케네스 엠. 골드만 | 만성 ｈｂｖ 감염의 치료 방법 |
| KR100900837B1 (ko) * | 2007-12-07 | 2009-06-04 | (주)두비엘 | 리포펩타이드와 폴리(ｉ:ｃ)를 아쥬반트로 포함하는 강력한백신 조성물 |
| US20120082719A1 (en) * | 2010-10-05 | 2012-04-05 | Sam Poon Ang | Compositions For Treating Chronic Viral Infections |
| US20120082720A1 (en) * | 2010-10-05 | 2012-04-05 | Sam Poon Ang | Compositions For Treating Chronic Viral Infections |
| KR101501583B1 (ko) * | 2013-03-29 | 2015-03-12 | 주식회사 차백신연구소 | 리포펩티드 및 폴리(ｉ:ｃ)를 포함하는 아쥬반트 및 이를 이용한 개선된 제형의 백신 조성물 |
| CA2982125A1 (en) * | 2015-04-07 | 2016-10-13 | Spring Bank Pharmaceuticals, Inc. | Compositions and methods for the treatment of hbv infection |
| CA3005127C (en) * | 2015-11-18 | 2023-01-24 | Immunovaccine Technologies Inc. | Adjuvanting systems and water-free vaccine compositions comprising a polyi:c polynucleotide adjuvant and a lipid-based adjuvant |
| KR102292147B1 (ko) * | 2020-11-18 | 2021-08-23 | 주식회사 차백신연구소 | 경구용 항바이러스제 및 리포펩타이드와 폴리(i:c) 아쥬반트를 포함한 치료백신을 유효성분으로 포함하는 만성 b형 간염의 예방 또는 치료용 약제학적 조성물, 약제학적 병용제제, 병용제 키트 |
-
2020
- 2020-11-18 KR KR1020200154793A patent/KR102292147B1/ko active Active
-
2021
- 2021-09-29 CN CN202180077439.2A patent/CN116568309B/zh active Active
- 2021-09-29 WO PCT/KR2021/013317 patent/WO2022108094A1/ko not_active Ceased
- 2021-09-29 EP EP21894866.9A patent/EP4230209B1/en active Active
- 2021-09-29 US US18/037,022 patent/US20230405112A1/en active Pending
- 2021-09-29 PL PL21894866.9T patent/PL4230209T3/pl unknown
- 2021-09-29 ES ES21894866T patent/ES2991384T3/es active Active
- 2021-09-29 MX MX2023005431A patent/MX2023005431A/es unknown
- 2021-09-29 AU AU2021382954A patent/AU2021382954B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4230209A1 (en) | 2023-08-23 |
| EP4230209C0 (en) | 2024-10-30 |
| AU2021382954A1 (en) | 2023-06-08 |
| MX2023005431A (es) | 2023-05-23 |
| EP4230209B1 (en) | 2024-10-30 |
| WO2022108094A1 (ko) | 2022-05-27 |
| AU2021382954B2 (en) | 2023-10-05 |
| KR102292147B1 (ko) | 2021-08-23 |
| ES2991384T3 (es) | 2024-12-03 |
| US20230405112A1 (en) | 2023-12-21 |
| CN116568309A (zh) | 2023-08-08 |
| CN116568309B (zh) | 2025-02-25 |
| EP4230209A4 (en) | 2023-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191957T1 (hr) | Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba | |
| EA201590166A1 (ru) | Комбинированная терапия для лечения рассеянного склероза | |
| JP2020514412A5 (pl) | ||
| JP2015505565A5 (pl) | ||
| BRPI0707235B1 (pt) | formulação de fentanil sublingual sem propelente, e, dispositivo de dose unitária para administração sublingual de uma formulação de fentanil sublingual | |
| PL373276A1 (pl) | Lek do stosowania przezskórnego do leczenia Zespołu Niespokojnych Nóg | |
| JP2017514911A5 (pl) | ||
| WO2020076760A3 (en) | Sphingoid compounds for use in the prophylaxis and/or therapy of a viral infection | |
| HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
| GB2613460A (en) | Methods for the prophylaxis and treatment of Covid and Covid-19 | |
| CL2024003616A1 (es) | Composición farmacéutica oral y uso para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| PL4230209T3 (pl) | Kompozycja farmaceutyczna, złożona formulacja farmaceutyczna i zestaw złożonej formulacji do zapobiegania przewlekłemu zapaleniu wątroby typu b lub leczenia takiego zapalenia, z których każde zawiera jako składnik czynny doustny środek przeciwwirusowy i szczepionkę terapeutyczną zawierającą lipopeptyd i adiuwant poli(i:c) | |
| JP2016505050A5 (pl) | ||
| MX2023005219A (es) | Formulacion solida. | |
| WO2006044968A3 (en) | Combination therapy for treating viral infections | |
| UA88446C2 (uk) | Препарат, що містить аскорбінову кислоту, для лікування та профілактики вагінальних грибкових інфекцій | |
| US10765650B2 (en) | Artificial saliva | |
| WO2016122288A3 (ko) | 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제 | |
| WO2006115770A3 (en) | Orally disintegrating pharmaceutical tablet formulations of olanzapine | |
| MX2007010886A (es) | Metodos y formulaciones de acarbosa para tratar constipacion cronica. | |
| JP2023543858A (ja) | 酸－塩基中和合剤を含む医薬組成物及びその使用 | |
| HRP20201436T1 (hr) | Makrogoli za davanje na sluznicu i njihove terapeutske primjene | |
| RU2011113733A (ru) | Производные 1-амино-алкилциклогексана для лечения когнитивного нарушения при шуме в ушах | |
| IL319025A (en) | Methods for treating or preventing endometriosis | |
| NZ703464A (en) | Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix |